BDBM652726 3-{[(1-aminoisoquinolin-5-yl)amino]methyl}-N-(3-hydroxypropyl)-N-[(1- isopropylpiperidin-4-yl)methyl]benzamide::US20240059691, Example 4441::US20240059691, Example 5441

SMILES CC(C)N1CCC(CN(CCCO)C(=O)c2cccc(CNc3cccc4c(N)nccc34)c2)CC1

InChI Key InChIKey=CQDVUJSXYFSSHR-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 652726   

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 200nMAssay Description:In vitro inhibition of Factor XIIa was determined using an IC50 assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol....More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 2.00E+3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 6.50E+3nMAssay Description:In vitro inhibition of Factor XIIa was determined using an IC50 assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol....More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 2.50E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 7.00E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 7.00E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652726BDBM652726(US20240059691, Example 4441 | US20240059691, Examp...)
Affinity DataIC50: 7.00E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent